1st and largest real-world comparison of ACURATE neo™ self-expanding valve and SAPIEN 3 balloon expandable valve.
STUDY DESIGN: 1:2 propensity-matched multicenter comparison of ACURATE neo (n = 311) and SAPIEN 3 (n = 622)
from three high-volume centers in Germany
1st comparison of ACURATE neo self-expanding valve and SAPIEN 3 balloon expandable valve
in patients with small aortic annuli.
STUDY DESIGN: 1:1 propensity-matched multicenter comparison of ACURATE neo (n = 92) and SAPIEN 3 (n = 92)
from five high-volume centers in Germany.
STUDY DESIGN: Analysis of 249 patients ACURATE neo (n=146) and SAPIEN 3 (n=103) treated with TF TAVI using the minimalist approach at Helsinki University Central Hospital to assess the success rate and safety of NDD at 90 days
and 1 year post-implantation.
STUDY DESIGN: Analysis of 296 patients with pre-existing complete RBBB ACURATE neo (n=98) and SAPIEN 3 (n=198) including a propensity-matched population of 130 patients: ACURATE neo (n=65) and SAPIEN 3 (n=65)
Outcomes of two next-generation self-expanding TAVI valves in real-world patients. STUDY DESIGN: 1:1 propensity score matched multicentercomparison of ACURATE neo (n = 251) and Evolut PRO (n = 251) from 24 international centers
STUDY DESIGN: Single-center study from Oxford, Great Britain, evaluating the impact of valve selection on procedural outcomes, length of stay (LoS), and 30-day mortality in 231 patients treated with either
ACURATE neo (n = 143) or Evolut R (n = 88).